Your session is about to expire
← Back to Search
NeuroVax Vaccine for Multiple Sclerosis
Study Summary
This trial is testing a new vaccine for Multiple Sclerosis in children to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From undefined Phase 2 trial • 40 Patients • NCT00003222Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My child has been diagnosed with Multiple Sclerosis.My MS has caused some disability but I can still walk, and I've had relapses recently.I am between 5 and 17 years old.I am between 5 and 17 years old.I have been diagnosed with Pediatric MS according to the McDonald criteria.I am currently taking Campath or Lemtrada.My gender does not limit my participation.
- Group 1: NeuroVax
- Group 2: IFA Incomplete Freund's Adjuvant
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Would this trial be considered an innovative research endeavor?
"NeuroVax has been a subject of clinical research since 2020, when Immune Response BioPharma, Inc. ran the first trial with 200 participants. Thereafter NeuroVax received Phase 2 & 3 drug approval; as it stands now, two active studies are taking place in one city and nation."
Have researchers previously conducted research into NeuroVax?
"At the moment, two NeuroVax trials are operational with one study moving into Phase 3. With a majority of sites located in San Diego, California, there are still two other centres conducting research on this therapeutic intervention."
Is this research endeavor still open to recruitment?
"Clinicaltrials.gov does not have any records of this trial actively recruiting participants, as the posting for it was first made on December 31st 2020 but then last edited on March 30th 2020. Nonetheless, 551 other clinical trials continue to search for volunteers."
How many participants are part of this clinical investigation?
"This trial is currently not enrolling any new candidates. It was initially posted on December 31st 2020, and the last update occurred on March 30th 2020. If you would like to explore other studies, 549 trials related to multiple sclerosis are recruiting participants right now, along with 2 NeuroVax initiatives seeking volunteers."
Is the age requirement for prospective participants above 25 years?
"This clinical trial only accepts participants that range in age from 5 to 17 years old."
To what demographic is this clinical trial available?
"In order to be considered for this research project, participants must have a diagnosis of multiple sclerosis and lie between 5-17 years old. Presently approximately 12 patients are being recruited."
Has NeuroVax been granted official sanction from the FDA?
"NeuroVax's safety is rated as a 1 based on limited available evidence, due to it being in the initial Phase 1 trial."
Share this study with friends
Copy Link
Messenger